RxDoctor Payments Data

Maria Lorena Anicete

Family · Houston, TXNPI 1114008968

Payments from drug & device makers

$2,694in general payments, 2019–2025

Across 146 payments — averaging $18.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$763
  • AbbVie$436
  • Boehringer Ingelheim$279
  • Amarin Pharma, Inc.$196
  • Johnson & Johnson$176
  • AstraZeneca$158
  • plus $687 from 15 others

What the payments were for

  • Food & beverage$2,694100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,694 in reported general payments places this provider in the 85th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide33$61,762
JardianceEmpagliflozin29$49,687
EliquisApixaban26$34,602
FarxigaDapagliflozin Propanediol26$26,235
OzempicSemaglutide19$22,664
JanuviaSitagliptin Phosphate18$18,941
XareltoRivaroxaban21$18,199
BrilintaTicagrelor11$11,165
Tresiba Flextouch U-100Insulin Degludec12$7,186
Albuterol Sulfate HfaAlbuterol Sulfate143$6,414
FenofibrateFenofibrate Nanocrystallized101$3,391
Celecoxib22$3,227
Diclofenac Sodium52$3,155
Gabapentin157$2,556
Atorvastatin Calcium312$2,415

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$763$84,42652 claims
Boehringer IngelheimJardiance$279$49,68729 claims
AstraZenecaFarxiga, Brilinta$158$37,40037 claims
PfizerEliquis$70$34,60226 claims
Johnson & JohnsonXarelto$176$18,19921 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 15,456 family providers in Texas.

Other family in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →